Capecitabine is commonly used in the treatment of several cancers, particularly colorectal cancer and breast cancer. It may be used as adjuvant therapy after surgery or for advanced and metastatic disease. In colorectal cancer, it is often prescribed alone or in combination with other chemotherapy agents. In breast cancer, it is frequently used when other treatments have not been effective or as part of combination regimens. Its oral administration makes it a convenient option for long-term treatment plans.

Capecitabine works as a prodrug that is converted into its active form, 5-fluorouracil (5-FU), within the body. This conversion occurs more efficiently in tumor tissues due to higher levels of specific enzymes. Once activated, 5-FU interferes with DNA synthesis by inhibiting thymidylate synthase, an enzyme necessary for DNA replication. This disruption prevents cancer cells from dividing and leads to cell death. Because cancer cells divide rapidly, they are more affected by this mechanism than most normal cells.

Capecitabine is administered orally in tablet form, usually taken twice daily within 30 minutes after a meal. The dosage is based on body surface area and the specific treatment protocol. It is typically given in cycles, such as two weeks of treatment followed by a one-week break, allowing the body time to recover. Patients should follow their doctor’s instructions carefully and avoid missing doses. Regular monitoring through blood tests is important to assess tolerance and effectiveness.

Capecitabine is generally well tolerated, but it can cause side effects, particularly with prolonged use. Common side effects include diarrhea, nausea, vomiting, fatigue, and loss of appetite. One of the characteristic side effects is hand-foot syndrome, which causes redness, swelling, and pain on the palms and soles. Patients may also experience mouth sores, low blood cell counts, and increased risk of infection. While most side effects are manageable, early recognition and communication with a healthcare provider are essential.

Capecitabine should not be used in patients with known hypersensitivity to fluorouracil or severe renal impairment. Caution is required in individuals with liver dysfunction, heart disease, or deficiencies in the enzyme dihydropyrimidine dehydrogenase (DPD), as this can increase the risk of severe toxicity. It is not recommended during pregnancy or breastfeeding due to potential harm to the fetus or infant. Patients should be closely monitored for side effects, and dose adjustments may be necessary based on tolerance.

Capecitabine offers a convenient and effective oral chemotherapy option for patients with certain cancers, combining the effectiveness of traditional chemotherapy with improved ease of use. Its targeted activation within tumor tissues helps optimize treatment outcomes while maintaining a manageable safety profile. However, proper adherence, monitoring, and medical guidance are essential to ensure safe and effective therapy. With the right approach, capecitabine continues to be a valuable option in modern cancer treatment.

Capecitabine is used to treat cancers such as colorectal cancer and breast cancer, either alone or in combination with other treatments.

It is converted into 5-fluorouracil (5-FU) in the body, which interferes with DNA synthesis and prevents cancer cells from growing and dividing.

It is taken orally, usually twice daily after meals, following a specific cycle prescribed by a doctor.

Common side effects include diarrhea, nausea, fatigue, and hand-foot syndrome, which can cause redness and pain in the hands and feet. These effects are often manageable with proper care and monitoring.

Hand-foot syndrome is a common side effect of Capecitabine that affects the palms of the hands and soles of the feet. It usually starts with redness, tingling, or a burning feeling, and may later cause swelling, dryness, pain, or sensitivity. In some cases, the skin can peel, crack, or form blisters, making daily activities uncomfortable. It happens because the medicine can irritate small blood vessels in these areas. Early care like using moisturizers, avoiding heat or pressure, and following your doctor’s advice can help manage symptoms and prevent them from getting worse.

Yes, it is a chemotherapy drug, but it is taken orally and designed to target cancer cells more specifically.

Yes, most side effects of capecitabine can be managed with supportive medications, dose adjustments, and regular monitoring by a healthcare provider.

Patients with severe kidney disease, hypersensitivity to fluorouracil, or certain enzyme deficiencies should avoid it unless advised otherwise by a doctor.